Medtronic's Resolute stent performs well in new study; London researchers get drugs across blood-brain barrier;

> Medtronic's ($MDT) Resolute drug-eluting stent showed no increased safety risk in a study of patients who discontinued antiplatelet therapy one month into their treatment--the results allow for an update to Resolute's CE mark but don't affect U.S. regulation. Release

> Researchers at the University College in London have found a way to deliver modified peptide drugs across the blood-brain barrier by attaching them to a group of fat molecules in nanofibers. Story

> HylaPharm, a spinout from the University of Kansas, is developing a cancer-drug delivery mechanism using nanoparticles that could make cancer treatments safer and more effective, most notably those that mestastize in the lymph nodes. More

> As part of its needle-free glucose monitoring system, Symphony, Echo Therapeutics ($ECTE) secured a patent for its Prelude SkinPrep System, the skin permeation component of the method. Release

> Drug delivery company Catalent broadened its global reach with a move to open two new facilities in China, focusing on its Softgel technologies and clinical supply solutions businesses. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.